Scholarlink

Background <p>Hepatitis C virus (HCV) poses a significant health and economic burden worldwide, with China bearing a considerable portion of this burden. Chinese treatment coverage remains low, and the full economic implications of achieving these goals are not well understood.</p> Objective <p>This study aims to evaluate the macroeconomic burden of HCV from 2023 to 2050, as well as the investments required, health benefits, cost-effectiveness, net economic benefit, and the impact on economic growth associated with achieving WHO hepatitis C intervention coverage targets more rapidly during this period.</p> Methods <p>A dynamic compartmental model was used to simulate the transmission, progression, and cascade of care for HCV patients in China. Intervention costs and healthcare costs were calculated using the cost-of-illness (COI) method. A health-augmented macroeconomic model projected macroeconomic outcomes. Scenarios were developed to evaluate different time points for achieving coverage targets.</p> Results <p>The projected macroeconomic burden of HCV from 2023 to 2050 is $1.17 trillion. Achieving WHO targets by 2030 is expected to spend $69.72 (95% UI $66.22–$73.68) billion but will avert 0.66(95% UI 0.58–0.74) million hepatocellular carcinoma (HCC) cases, and 1.10(95% UI 1.03–1.18) million HCV-related deaths compared to status quo. Faster achievement of coverage targets is associated with investments becoming cost-effective sooner and facilitating greater economic growth.</p> Conclusion <p>Achieving the WHO Global Health Sector Strategy diagnosis and treatment coverage targets by 2030 in China is projected to be cost-effective and result in significant health and economic benefits. The findings underscore the importance of increased investment in hepatitis C elimination efforts in China.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The macroeconomic burden of hepatitis C and the economic benefit of accelerated investments in China

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月13日

查看全文
  • Yun Bao,
  • Ying Chen,
  • Huajie Jin,
  • Chi Zhang,
  • Lingli Zhang,
  • Bin Wu

摘要

Background

Hepatitis C virus (HCV) poses a significant health and economic burden worldwide, with China bearing a considerable portion of this burden. Chinese treatment coverage remains low, and the full economic implications of achieving these goals are not well understood.

Objective

This study aims to evaluate the macroeconomic burden of HCV from 2023 to 2050, as well as the investments required, health benefits, cost-effectiveness, net economic benefit, and the impact on economic growth associated with achieving WHO hepatitis C intervention coverage targets more rapidly during this period.

Methods

A dynamic compartmental model was used to simulate the transmission, progression, and cascade of care for HCV patients in China. Intervention costs and healthcare costs were calculated using the cost-of-illness (COI) method. A health-augmented macroeconomic model projected macroeconomic outcomes. Scenarios were developed to evaluate different time points for achieving coverage targets.

Results

The projected macroeconomic burden of HCV from 2023 to 2050 is $1.17 trillion. Achieving WHO targets by 2030 is expected to spend $69.72 (95% UI $66.22–$73.68) billion but will avert 0.66(95% UI 0.58–0.74) million hepatocellular carcinoma (HCC) cases, and 1.10(95% UI 1.03–1.18) million HCV-related deaths compared to status quo. Faster achievement of coverage targets is associated with investments becoming cost-effective sooner and facilitating greater economic growth.

Conclusion

Achieving the WHO Global Health Sector Strategy diagnosis and treatment coverage targets by 2030 in China is projected to be cost-effective and result in significant health and economic benefits. The findings underscore the importance of increased investment in hepatitis C elimination efforts in China.